This cost-utility analysis reports on the effect of quality of life on the value of screening all new patients with colorectal cancer for Lynch Syndrome.
Kathryn A. Phillips, PhD
Advertisement
Articles by Kathryn A. Phillips, PhD
A study of major US private payers showed an important role and considerable shortcomings of external health technology assessment in coverage decisions on personalized medicine.
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
Targeting Oxidative Stress Could Fill a Gap in the Vitiligo Treatment Toolbox
3
How Hospital Specialty Pharmacies Are Closing the Pharmacy Desert Gap
4
Tisagenlecleucel Yields Promising Disease-Free Survival in High-Risk Pediatric ALL: Shannon L. Maude, MD, PhD
5